Introduction
Hematopoietic malignancies can be encountered in the breast and can occasionally mimic primary breast cancers.
Although lymphomas are generally considered as tumors of lymph nodes about 25-40% arise at extranodal sites [1, 2] and it's important to distinguish them from secondary extranodal involvement by disseminated nodal disease. Despite there isn't a precise and agreed definition, extranodal lymphomas are considered all lymphomas confined to a solitary extranodal site (and possibly its contiguous lymph nodes) or, at least and less strictly, Primary breast non-Hodgkin lymphoma. A report of an unusual case a lymphoma which presents the main bulk of diseases at an extranodal site [2, 3] . Wiseman and Liao [4] have proposed that the diagnosis of primary breast non-Hodgkin lymphoma (PBNHL) must satisfy three criteria: 1) adequate pathologic evaluation, 2) both mammary tissue and lymphomatous infiltrate in close association, and 3) exclusion of either systemic lymphoma or previous extramammary lymphoma. PBNHL are mainly diffuse large B-cell non-Hodgkin lymphoma (B-DLC-NHL) and are very rare, accounting for 2.2% of all extranodal lymphomas [1] and for 0.04% to 0.5% of malignant breast neoplasms [4] [5] [6] [7] . The most common symptom of primary breast lymphoma is a palpable lump but it may also present as breast enlargement [8] . The natural history of primary breast NHL is different from that of extra nodal NHL at other sites, because of its rapid progression and worse prognosis [9] ; Giardini et al. have reported a total five-year survival rate of 43% [10] .
Case report
We report a case of a 60 year old female who developed a right A written consensus was obtained by the patient before each study.
Discussion
Primary lymphomas of the breast are uncommon [1, 11] and, although rare, bilateral breast involvement has also been reported [12] . The old history of breast B-DLC-NHL relapsed twice after therapy, firstly at the same breast and subsequently at the other, makes this case of unique interest also because of the concurrent use of radiologic and nuclear medicine imaging. Despite the radiologic features are non-specific and the diagnosis cannot be made on the basis of imaging only, it's very relevant in establishing disease extent, possible involvement of other sites and therapy planning. Therapeutic procedures mainly rely on chemotherapy and radiotherapy [8, 13, 14] while surgery has had a progressive decline [15] [16] [17] . PBNHL doesn't show specific mammographic features; most commonly it has been reported as well-circumscribed lesion without calcifications or desmoplastic reaction, but also as lesion with sharp or minimally irregular margins, and less commonly as diffuse increased parenchymal density with skin thickening or as miliary densities [8, 13, [18] [19] [20] . Bilateral miliary densities on mammography have been reported in secondary involvement of the breast by NHL [20] . At ultrasonography examination breast lymphomas are generally described as masses that could be well or poorly defined, with an hypo-or hyperechoic aspect and showing both a focal and diffuse parenchymal involvement [21, 22] . In a recent study Li et described multiple well-or ill-defined nonspiculated hypointense masses on T1 weighted images [19, 22] . Darnell et al. described a single, large, well-circumscribed mass, isointense relative to parenchyma on T1 images, associated with enhancing skin thickening [9] . A possible important role of MR seems to be its ability to evaluate multicentricity and multifocality of lesions as demonstrated by Kiresi et al. [24] ; moreover, Espinosa et al. showed that MR could be more accurate than mammography and ultrasonography in detecting and staging multifocal breast lymphoma and it's very useful in the therapy response evaluation [25] . Although in the past 67Ga-citrate scintigraphy was an important tool for the evaluation of lymphomas, nowadays its role is very limited and it's not recommendable for dosimetric concerns and diagnostic accuracy; despite this, in a recent study by Takemura et al, published in 2009, a PBNHL was studied with this tracer [26] .
F18-FDG-PET/CT role in the management of high-grade NHL and Hodgkin Disease is well established and many data are available in literature about its usefulness in evaluating extranodal lymphomas (bone, nasal region, pituitary, testis, ocular region, thyroid, adrenal) [27] [28] [29] [30] [31] [32] [33] . There are few reports on the role of F18-FDG-PET/CT for the management of PBNHL [34] [35] [36] [37] [38] .
Most studies are case reports with few exceptions [38, 39] and in all cases is reported high FDG uptake. Yang et al. [38] 
